by Noah Blaine

Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

– Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan –

source https://finance.yahoo.com/news/alexion-bridgebio-announce-japanese-license-113000690.html?.tsrc=rss

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.